Description
-
Product Overview:
A balanced, co-lyophilized 1:1 synergistic research formulation containing 5 mg CJC-1295 without DAC (Mod GRF 1-29) and 5 mg Ipamorelin. Formulated for investigating somatotrophic cellular signaling cascades, this reagent permits simultaneous in-vitro evaluation of GHRH receptor binding alongside selective ghrelin/GHS receptor activation without triggering unspecific anterior pituitary hormone cascades.
-
Specifications:
-
Composition: 5 mg CJC-1295 (without DAC / Mod GRF 1-29) + 5 mg Ipamorelin
-
Total Mass: 10 mg Lyophilized Cake
-
Purity: > 99.0% per peptide sequence (HPLC/MS verified)
-
Storage: Store desiccated at -20°C. Protect from heat and direct light.
-
-
Compliance Disclaimer: For laboratory research and analytical testing only. Not for human, clinical, therapeutic, or diagnostic administration.
- Latest COA available here.
